Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Breast Neoplasms 81Neoplasms 75Colorectal Neoplasms 65Neoplasm Metastasis 64Leukemia, Myeloid, Acute 62Prostatic Neoplasms 59Recurrence 53Pancreatic Neoplasms 51Ovarian Neoplasms 50Multiple Myeloma 50Triple Negative Breast Neoplasms 36Lung Neoplasms 36Melanoma 35Squamous Cell Carcinoma of Head and Neck 33Lymphoma, Non-Hodgkin 33Glioblastoma 31Carcinoma, Renal Cell 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, Large B-Cell, Diffuse 28Lymphoma 28Endometrial Neoplasms 28Carcinoma, Hepatocellular 28Stomach Neoplasms 26Small Cell Lung Carcinoma 26Leukemia, Lymphocytic, Chronic, B-Cell 26Myelodysplastic Syndromes 24Lymphoma, Follicular 24Lymphoma, B-Cell 24Sarcoma 23

Interventions

durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pathologic Complete Response × 90 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07538206 2026-04-20

Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma

Tang-Du Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Head & Neck

Pathologic Complete Response, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡